News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Features Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too Michael O'Riordan December 09, 2019
News Conference News AHA 2019 Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT Yael L. Maxwell November 17, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2019 Todd Neale October 31, 2019
News Daily News Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe Yael L. Maxwell October 16, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2019 Shelley Wood October 01, 2019
News Conference News TCT 2019 GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients? Todd Neale September 30, 2019
News Opinion Off Script TCT 2019 Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall Kwan S. Lee September 29, 2019
Presentation TCT 2019 STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice? Presenter: Aditya Kapoor September 28, 2019
Presentation TCT 2019 GLOBAL LEADERS: Ticagrelor Monotherapy vs. DAPT After PCI in TWILIGHT-Like Patients Presenter: Yoshinobu Onuma September 27, 2019
Presentation TCT 2019 Take Home for Clinicians: DM and STEMI Presenter: Dominick Angiolillo September 26, 2019
Presentation TCT 2019 COMPLETE Trial: Focus on STEMI and MVD Presenter: Shamir Mehta September 26, 2019
Presentation TCT 2019 The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease Presenter: Marc Bonaca September 26, 2019
Presentation TCT 2019 Reconciling Adjudicated Data Within a Global Trial Presenter: Marco Valgimigli September 26, 2019
Presentation TCT 2019 Transitioning to Monotherapy in Patients After PCI Presenter: Pascal Vranckx September 26, 2019
News Conference News TCT 2019 Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT Caitlin E. Cox September 26, 2019